These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 16268466

  • 1. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
    Eriksson H, Lundström T, Wåhlander K, Clason SB, Schulman S, THRIVE III Investigators.
    Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
    [Abstract] [Full Text] [Related]

  • 2. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.
    Wåhlander K, Eriksson H, Lundström T, Billing Clason S, Wall U, Nyström P, Wessman P, Schulman S, THRIVE III Investigators.
    Br J Haematol; 2006 Apr; 133(1):68-77. PubMed ID: 16512831
    [Abstract] [Full Text] [Related]

  • 3. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H, THRIVE III Investigators.
    N Engl J Med; 2003 Oct 30; 349(18):1713-21. PubMed ID: 14585939
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW, EXULT A Study Group.
    N Engl J Med; 2003 Oct 30; 349(18):1703-12. PubMed ID: 14585938
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J.
    Arch Intern Med; 2006 Apr 24; 166(8):853-9. PubMed ID: 16636210
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
    Harenberg J, Ingrid J, Tivadar F.
    Isr Med Assoc J; 2002 Nov 24; 4(11):1003-5. PubMed ID: 12489490
    [Abstract] [Full Text] [Related]

  • 10. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV, Bounameaux H.
    Semin Vasc Med; 2005 Aug 24; 5(3):276-84. PubMed ID: 16123915
    [Abstract] [Full Text] [Related]

  • 11. The role of ximelagatran in the treatment of venous thromboembolism.
    Schulman S.
    Pathophysiol Haemost Thromb; 2005 Aug 24; 34 Suppl 1():18-24. PubMed ID: 15812200
    [Abstract] [Full Text] [Related]

  • 12. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
    Harenberg J, Jörg I, Weiss C.
    Int J Toxicol; 2006 Aug 24; 25(3):165-9. PubMed ID: 16717032
    [Abstract] [Full Text] [Related]

  • 13. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D.
    Thromb Haemost; 2002 Feb 24; 87(2):231-7. PubMed ID: 11858482
    [Abstract] [Full Text] [Related]

  • 14. Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
    Harenberg J, Jörg I, Weiss C.
    Eur J Clin Pharmacol; 2006 Mar 24; 62(3):173-7. PubMed ID: 16416154
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Ximelagatran for treatment of venous thromboembolism].
    Harenberg J, Fenyvesi T, Jörg I.
    Hamostaseologie; 2002 Aug 24; 22(3):25-9. PubMed ID: 12215758
    [Abstract] [Full Text] [Related]

  • 17. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC, Perry CM, Faulds D.
    Drugs; 2004 Aug 24; 64(6):649-78. PubMed ID: 15018597
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ximelagatran: an oral direct thrombin inhibitor.
    Dager WE, Vondracek TG, McIntosh BA, Nutescu EA.
    Ann Pharmacother; 2004 Nov 24; 38(11):1881-97. PubMed ID: 15383641
    [Abstract] [Full Text] [Related]

  • 20. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group.
    Circulation; 2004 Aug 17; 110(7):874-9. PubMed ID: 15289368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.